Core Viewpoint - Southbound funds have significantly reduced their holdings in Health Road (02587.HK), indicating a potential shift in investor sentiment towards the company [1]. Group 1: Shareholding Changes - On November 12, southbound funds reduced their holdings by 279.25 thousand shares, marking a decrease of 1.53% [2]. - Over the past five trading days, there have been reductions in holdings for four days, totaling a net decrease of 942.2 thousand shares [1]. - In the last 20 trading days, there were 15 days of reductions, with a cumulative net decrease of 1,959.4 thousand shares [1]. Group 2: Current Holdings - As of now, southbound funds hold 1.8 million shares of Health Road, which represents 20.44% of the company's total issued ordinary shares [1]. Group 3: Company Overview - Health Road Holdings Limited primarily engages in providing enterprise services, digital marketing services, and health care services [2]. - The company operates through three segments: enterprise services and digital marketing, health care services, and other health services and products [2]. - The enterprise services and digital marketing segment includes content services, IT services, and digital marketing services [2].

Core Viewpoint - Southbound funds have reduced their holdings in Health Road (02587.HK) by 203.15 million shares on November 4, with a total net reduction of 345.0 million shares over the last five trading days and 891.4 million shares over the last twenty trading days [1][2]. Group 1: Shareholding Changes - As of November 4, 2025, southbound funds hold 190 million shares of Health Road, accounting for 21.63% of the company's total issued ordinary shares [1]. - The shareholding changes over the last five trading days include a reduction of 203.15 million shares on November 4, a reduction of 142.35 million shares on November 3, an increase of 73.30 million shares on October 31, a reduction of 110.10 million shares on October 30, and an increase of 37.30 million shares on October 28 [2]. Group 2: Company Overview - Health Road Holdings Limited is primarily engaged in providing enterprise services, digital marketing services, and health care services as an investment holding company [2]. - The company operates through three main segments: enterprise services and digital marketing services, health care services, and other health services and products sold through various online and offline channels [2].

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Health Road (02587.HK) by 226.15 million shares on October 27, with a total net reduction of 359.9 million shares over the past five trading days and 763.8 million shares over the past twenty trading days [1][2] - As of now, southbound funds hold 193 million shares of Health Road, accounting for 22.03% of the company's total issued ordinary shares [1][2] - The company operates primarily in three segments: enterprise services and digital marketing services, health care services, and other health services and products [2] Group 2 - The enterprise services and digital marketing services segment includes content services, information technology services, and digital marketing services [2] - The health care services segment provides medical support services and value-based medical services [2] - The other segment offers various health services and products through online and offline channels, such as patient visitation services and nutritional supplements sales [2]

Group 1 - The company expects to record a profit of no less than RMB 6 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 57.28 million for the same period in 2024 [1] - The anticipated loss in 2024 is primarily due to changes in the redemption liability value from the termination of the priority rights of convertible redeemable preferred shares and expenses incurred during the listing preparation [1] - Despite the expected profit, the company forecasts a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] Group 2 - The board believes the expected decrease in revenue and gross profit is mainly due to a reduction in content service revenue, as some clients have shifted to direct marketing strategies, reducing reliance on Real World Evidence (RWS) support services [2] - Increased competition in the generic drug industry has led to a shift of resources towards commercialization, resulting in budget cuts for RWS services from some clients [2] - The decline in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure and classification [2] - A decrease in digital marketing service revenue is primarily due to the economic downturn, prompting some clients to reduce advertising and marketing expenditures [2]

Core Viewpoint - The company expects to achieve a profit of no less than RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1] Group 1: Financial Performance - The company anticipates a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to decrease by about 8% to 12% compared to a gross profit of approximately RMB 184 million for the six months ending June 30, 2024 [1] Group 2: Revenue Decline Factors - The anticipated revenue decline is mainly due to a reduction in content service revenue, as some clients are shifting to direct marketing strategies, reducing their reliance on Real World Evidence (RWS) support services [2] - The decrease in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure leading to reduced income from comprehensive healthcare service packages [2] - Digital marketing service revenue is also expected to decline due to economic downturns prompting clients to cut advertising and marketing expenditures [2]

Core Viewpoint - The company expects to achieve a profit of at least RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1] Group 1: Financial Performance - The company anticipates a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to decrease by about 8% to 12% compared to a gross profit of approximately RMB 184 million for the six months ending June 30, 2024 [1] Group 2: Revenue Decline Factors - The anticipated revenue decline is mainly due to a reduction in content service revenue, as some clients are shifting to direct marketing strategies, reducing their reliance on Real World Evidence (RWS) support services [2] - The decrease in value-added medical service revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure [2] - Digital marketing service revenue is expected to decline due to economic downturns, leading some clients to cut advertising and marketing expenditures [2]